SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have cardioprotective effects without acting directly on the myocardium. Objectives: The purpose of the study was to evaluate the impact of SGLT2i on myocardial glucose utilization. Methods: This retrospective propensity-matched cohort...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | JACC: Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772963X25004405 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849254265267159040 |
|---|---|
| author | Brett W. Sperry, MD Yazan Almohtasib, MD Ramy Ghaly, MD Mohammad Abdel Jawad, MD Andrew J. Sauer, MD Timothy M. Bateman, MD |
| author_facet | Brett W. Sperry, MD Yazan Almohtasib, MD Ramy Ghaly, MD Mohammad Abdel Jawad, MD Andrew J. Sauer, MD Timothy M. Bateman, MD |
| author_sort | Brett W. Sperry, MD |
| collection | DOAJ |
| description | Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have cardioprotective effects without acting directly on the myocardium. Objectives: The purpose of the study was to evaluate the impact of SGLT2i on myocardial glucose utilization. Methods: This retrospective propensity-matched cohort study examined subjects who underwent whole-body 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography for oncologic purposes between 2016 and 2024. A 1:1 propensity match analyzed positron emission tomography-derived myocardial FDG uptake, maximum myocardial standardized uptake value (SUV), and total myocardial glycolysis in SGLT2i-treated vs untreated patients. Results: Among 6,747 subjects, 187 were actively prescribed SGLT2i and matched with 187 who were not. Mean age was 68.4 ± 9.7 years, 57.5% were males, 81.8% had diabetes, and 41.4% had heart failure. Myocardial FDG uptake (to quantify glucose utilization) was absent in 64.7% of patients on SGLT2i and 37.4% not on SGLT2i (P < 0.001), despite higher prescan glucose in those receiving SGLT2i (124 vs 110 mg/dL). SUVmax (5.4 vs 5.8, P = 0.004), volume of myocardial FDG uptake (0.8 cm3 vs 4.6 cm3, P = 0.001), and total myocardial glycolysis (1.6 g vs 20.6 g, P < 0.001) were significantly lower in patients treated with SGLT2i vs those untreated. SGLT2i use blunted insulin-induced increases in total myocardial glycolysis (P-interaction 0.036). There was no difference in background SUVmax and SUVmean in the blood pool and liver. Conclusions: SGLT2i use was associated with a greater suppression of myocardial glucose without affecting background tissue glycolysis despite higher prescan glucose levels. These findings add to the understanding of the effect of SGLT2i on the myocardium and may have implications with respect to cardiac imaging protocols that require glucose manipulation. |
| format | Article |
| id | doaj-art-db66ccc6bb0f49678111dc4f4eae1568 |
| institution | Kabale University |
| issn | 2772-963X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JACC: Advances |
| spelling | doaj-art-db66ccc6bb0f49678111dc4f4eae15682025-08-20T03:56:04ZengElsevierJACC: Advances2772-963X2025-08-014810201610.1016/j.jacadv.2025.102016SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose MetabolismBrett W. Sperry, MD0Yazan Almohtasib, MD1Ramy Ghaly, MD2Mohammad Abdel Jawad, MD3Andrew J. Sauer, MD4Timothy M. Bateman, MD5Saint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USA; Address for correspondence: Dr Brett W. Sperry, Saint Luke's Mid America Heart Institute, 4330 Wornall Road, Suite 2000, Kansas City, Missouri 64111, USA.Saint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USASaint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USASaint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USASaint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USASaint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USABackground: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have cardioprotective effects without acting directly on the myocardium. Objectives: The purpose of the study was to evaluate the impact of SGLT2i on myocardial glucose utilization. Methods: This retrospective propensity-matched cohort study examined subjects who underwent whole-body 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography for oncologic purposes between 2016 and 2024. A 1:1 propensity match analyzed positron emission tomography-derived myocardial FDG uptake, maximum myocardial standardized uptake value (SUV), and total myocardial glycolysis in SGLT2i-treated vs untreated patients. Results: Among 6,747 subjects, 187 were actively prescribed SGLT2i and matched with 187 who were not. Mean age was 68.4 ± 9.7 years, 57.5% were males, 81.8% had diabetes, and 41.4% had heart failure. Myocardial FDG uptake (to quantify glucose utilization) was absent in 64.7% of patients on SGLT2i and 37.4% not on SGLT2i (P < 0.001), despite higher prescan glucose in those receiving SGLT2i (124 vs 110 mg/dL). SUVmax (5.4 vs 5.8, P = 0.004), volume of myocardial FDG uptake (0.8 cm3 vs 4.6 cm3, P = 0.001), and total myocardial glycolysis (1.6 g vs 20.6 g, P < 0.001) were significantly lower in patients treated with SGLT2i vs those untreated. SGLT2i use blunted insulin-induced increases in total myocardial glycolysis (P-interaction 0.036). There was no difference in background SUVmax and SUVmean in the blood pool and liver. Conclusions: SGLT2i use was associated with a greater suppression of myocardial glucose without affecting background tissue glycolysis despite higher prescan glucose levels. These findings add to the understanding of the effect of SGLT2i on the myocardium and may have implications with respect to cardiac imaging protocols that require glucose manipulation.http://www.sciencedirect.com/science/article/pii/S2772963X25004405cardiomyopathydiabetesfatty acidsheart failureketone bodymetabolic syndrome |
| spellingShingle | Brett W. Sperry, MD Yazan Almohtasib, MD Ramy Ghaly, MD Mohammad Abdel Jawad, MD Andrew J. Sauer, MD Timothy M. Bateman, MD SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism JACC: Advances cardiomyopathy diabetes fatty acids heart failure ketone body metabolic syndrome |
| title | SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism |
| title_full | SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism |
| title_fullStr | SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism |
| title_full_unstemmed | SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism |
| title_short | SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism |
| title_sort | sglt2 inhibitor treatment is associated with reduced cardiac glucose metabolism |
| topic | cardiomyopathy diabetes fatty acids heart failure ketone body metabolic syndrome |
| url | http://www.sciencedirect.com/science/article/pii/S2772963X25004405 |
| work_keys_str_mv | AT brettwsperrymd sglt2inhibitortreatmentisassociatedwithreducedcardiacglucosemetabolism AT yazanalmohtasibmd sglt2inhibitortreatmentisassociatedwithreducedcardiacglucosemetabolism AT ramyghalymd sglt2inhibitortreatmentisassociatedwithreducedcardiacglucosemetabolism AT mohammadabdeljawadmd sglt2inhibitortreatmentisassociatedwithreducedcardiacglucosemetabolism AT andrewjsauermd sglt2inhibitortreatmentisassociatedwithreducedcardiacglucosemetabolism AT timothymbatemanmd sglt2inhibitortreatmentisassociatedwithreducedcardiacglucosemetabolism |